Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2018

View Archived Issues

7 Hills Pharma receives support from NIH to develop next-generation integrin activator

Luye cleared for phase I trials in China with LY-03012

Cytokinetics presents data from phase II study of reldesemtiv

Novel collaborative agreement to develop Nanotaxi-formulated DNA dengue vaccine

Missense mutations in GLIS1 gene are linked to malformation syndromes

Phase II dose of BAL-101553 defined in solid tumors trial

GSX2 gene identified as causative of basal ganglia agenesis

Moxetumomab pasudotox pivotal trial data in relapsed/refractory hairy cell leukemia reported

Loss-of-function mutation in TCF12 gene linked to autosomal dominant Kallmann syndrome

Aquinnah Pharmaceuticals obtains NINDS grant to develop ALS drugs

New phase II trial studies arimoclomol for Gaucher's disease

Atossa completes dosing in phase I study of topical endoxifen

Immune Design opens phase III study of CMB-305 for synovial sarcoma

FDA approves use of Cinryze to prevent angioedema attacks in pediatric patients with HAE

PATH and SD Biosensor partner on new diagnostic for G6PD deficiency in malaria

Kiyatec initiates 3D-PREDICT study with EV3D assay

Xalud initiates phase I trial of XT-150 for osteoarthritic pain

TG Therapeutics and Novimmune enter global agreement to develop and commercialize TG-1801

Insights into the orthosteric and allosteric action of C5aR antagonists to guide drug development

Teijin Pharma presents CDK4/cyclin D3 and/or CDK6/cyclin D3 inhibitors

Amgen discovers apelin receptor agonists

MTHFD2 inhibitors identified at Daiichi Sankyo

Shanghai Meton Pharmaceutical patents NADP+ inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...